Market Closed -
Bombay S.E.
06:00:47 2024-05-14 am EDT
5-day change
1st Jan Change
1,636
INR
-3.05%
+1.60%
+23.67%
Sales 2024
200B
2.4B
Sales 2025 *
217B
2.59B
Capitalization
769B
9.21B
Net income 2024
19.14B
229M
Net income 2025 *
23.92B
286M
EV / Sales 2024
3.68
x
Net Debt
2024
*
24.9B
298M
Net Debt
2025
*
8.41B
101M
EV / Sales 2025 *
3.59
x P/E ratio 2024
38.6
x
P/E ratio 2025 *
32.4
x
Employees
20,933
Yield 2024 *
0.42%
Yield 2025 *
0.5%
Free-Float
52.83%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
5 minutes 15 minutes 30 minutes 1 hour 1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
Lupin Relaunches Mirabegron ER Tablets in US
May. 12
MT
Nomura Adjusts Lupin’s Price Target to INR1,952 From INR1,949, Keeps at Buy
May. 09
MT
Lupin Limited Announces Board Appointments
May. 09
CI
Jefferies Adjusts Lupin’s Price Target to INR1,535 From INR1,460 Keeps at Hold
May. 08
MT
Transcript : Lupin Limited, Q4 2024 Earnings Call, May 07, 2024
May. 07
Lupin's Consolidated Profit Climbs in Fiscal Q4; Shares Dip 4%
May. 07
MT
Indian drugmaker Lupin misses quarterly profit estimates as costs rise
May. 06
RE
Lupin Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024
May. 06
CI
Lupin Limited Reports Earnings Results for the Full Year Ended March 31, 2024
May. 06
CI
Lupin Limited Receives an Order from Office of the State Tax Inspector, Jurisdiction: Ghatak 56: Range - 14: Division - 6: Gujarat
Apr. 30
CI
Lupin Receives US FDA Inspection Report for Aurangabad, India Manufacturing Facility
Apr. 23
MT
INDIA STOCKS-Indian shares rise tracking Asia rebound; drop in HDFC Bank caps gains
Apr. 22
RE
Lupin Launches Mirabegron Extended-Release Tablets in US
Apr. 21
MT
Lupin Limited Announces Launch of Mirabegron Extended-Release Tablets, 25 Mg, in the United States, After Having Received an Approval from the United States Food and Drug Administration
Apr. 20
CI
US FDA Clears Lupin's API Plant in Gujarat, India, Following GMP Inspection
Apr. 12
MT
More news
EXCLUSIVA-Eli Lilly podría lanzar un fármaco contra la obesidad en India el próximo año: presidente ejecutivo
Feb. 28
Wall Street fait relâche
Jan. 15
En Direct des Marchés : ArcelorMittal, Airbus, Atos, Casino, Deutsche Bank, SoftwareOne, Baidu...
Jan. 15
EN DIRECTO DESDE LOS MERCADOS: ArcelorMittal, Airbus, Apple, FedEx, EQT, Citigroup, Deutsche Bank, SoftwareOne, Baidu...
Jan. 15
Accenture : accompagne la transformation de Lupin Limited
22-06-20
More news 1 day -2.36%
1 week +2.33%
Current month +0.15%
1 month +2.47%
3 months +2.39%
6 months +40.79%
Current year +24.56%
More quotes
Managers
Title Age Since
Chief Executive Officer
56
96-12-31
President
-
-
Director of Finance/CFO
59
07-08-12
Members of the board
Title Age Since
Director/Board Member
74
15-10-26
Director/Board Member
69
21-01-27
Director/Board Member
50
95-12-31
More insiders
Date
Price
Change
Volume
24-05-14
1,636
-3.05%
45 301
24-05-13
1,688
+4.84%
99,756
24-05-10
1,610
+1.62%
56,154
24-05-09
1,584
-1.95%
16,056
24-05-08
1,616
+0.33%
27,302
Delayed Quote
Bombay S.E., May 14, 2024 at 02:50 am EDT
More quotes
Lupin Limited is a leading Indian pharmaceutical group. Its products are used to treat tuberculosis, diabetes, asthma, cardiovascular diseases, infections, etc. The group's activity is organized around 2 areas:
- design and production of generic and brand-name formulations;
- production of active pharmaceutical ingredients.
At the end of March 2022, the group had 15 production sites India (12), the United States, Mexico and Brazil.
Net sales break down geographically as follows: India (39.4%), the United States (34.1%) and other (26.5%).
More about the company
Last Close Price
1,688
INR
Average target price
1,551
INR
Spread / Average Target
-8.12%
Consensus
1st Jan change
Capi.
+24.56% 9.21B +29.98% 682B +30.34% 586B -3.52% 364B +18.59% 327B +4.07% 285B +16.21% 240B +9.66% 209B -6.83% 203B +7.09% 165B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1